Aspire Biopharma (NASDAQ:ASBP – Get Free Report) and Continental (OTCMKTS:CTTAY – Get Free Report) are both consumer discretionary companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, risk, profitability and institutional ownership.
Analyst Recommendations
This is a summary of recent ratings and target prices for Aspire Biopharma and Continental, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Aspire Biopharma | 1 | 0 | 0 | 0 | 1.00 |
| Continental | 0 | 5 | 4 | 0 | 2.44 |
Risk and Volatility
Aspire Biopharma has a beta of 0.17, meaning that its stock price is 83% less volatile than the S&P 500. Comparatively, Continental has a beta of 1.39, meaning that its stock price is 39% more volatile than the S&P 500.
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Aspire Biopharma | $10,000.00 | 1,164.80 | -$24.48 million | ($69.62) | -0.12 |
| Continental | $22.26 billion | 0.72 | -$186.68 million | ($0.30) | -26.60 |
Aspire Biopharma has higher earnings, but lower revenue than Continental. Continental is trading at a lower price-to-earnings ratio than Aspire Biopharma, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Aspire Biopharma and Continental’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Aspire Biopharma | -11,362.21% | N/A | -177.59% |
| Continental | -1.36% | -10.86% | -2.63% |
Institutional and Insider Ownership
19.2% of Aspire Biopharma shares are held by institutional investors. Comparatively, 0.0% of Continental shares are held by institutional investors. 5.8% of Aspire Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Summary
Continental beats Aspire Biopharma on 7 of the 13 factors compared between the two stocks.
About Aspire Biopharma
Aspire Biopharma Holdings, Inc., early-stage biopharmaceutical company, engages in developing and marketing of disruptive technology for delivery mechanisms for do no harm drugs in the United States. The company provides Sublingual Aspirin Product, which addresses cardiology emergencies and pain management. It develops formulation for a sublingually administered melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide, as well as formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and several other classes of drugs. The company was founded in 2021 and is based in Humacao, Puerto Rico.
About Continental
Continental Aktiengesellschaft, a technology company, offers intelligent solutions for vehicles, machines, traffic, and transportation worldwide. It operates through four sectors: Automotive, Tires, ContiTech, and Contract Manufacturing. The company offers safety, brake, chassis, motion, and motion control systems; solutions for assisted and automated driving; display and operating technologies; and audio and camera solutions for the vehicle interior, as well as intelligent information and communication technology solutions. It also provides tires for cars, trucks, buses, two-wheel, and specialist vehicles, as well as digital tire monitoring and management systems; and engages in retail of tires. In addition, the company develops products and systems made from rubber, plastic, metal and textiles for the energy, agriculture, and construction, as well as interior design, automotive, transportation, and railway engineering sectors; and provides contract manufacturing services. The company was formerly known as Continental-Caoutchouc- und Gutta-Percha Compagnie. Continental Aktiengesellschaft was founded in 1871 and is headquartered in Hanover, Germany.
Receive News & Ratings for Aspire Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aspire Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
